Genetically engineered nano‐melittin vesicles for multimodal synergetic cancer therapy

Melittin, the principal constituent in bee venom, is an attractive candidate for cancer therapy. However, its clinical applications are limited by hemolysis, nonspecific cytotoxicity, and rapid metabolism. Herein, a novel genetically engineered vesicular antibody‐melittin (VAM) drug delivery platfor...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Jianzhong, Liu, Xue, Xia, Yutian, Xu, Shuyu, Liu, Xuan, Xiao, Haiqing, Wang, Xiaoyong, Liu, Chao, Liu, Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2023
Materias:
Special Issue Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658496/
https://www.ncbi.nlm.nih.gov/pubmed/38023709
http://dx.doi.org/10.1002/btm2.10482

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658496/
https://www.ncbi.nlm.nih.gov/pubmed/38023709
http://dx.doi.org/10.1002/btm2.10482

Ejemplares similares